Calcineurin inhibitor
Calcineurin inhibitor refers to a class of immunosuppressive therapy that suppresses T-cell activation by inhibiting calcineurin, a calcium-dependent phosphatase involved in the transcription of interleukin-2 and other cytokines.
Calcineurin inhibitor refers to a class of immunosuppressive therapy that suppresses T-cell activation by inhibiting calcineurin, a calcium-dependent phosphatase involved in the transcription of interleukin-2 and other cytokines. In clinical medicine, calcineurin inhibitors are central components of many transplant immunosuppression regimens, particularly in solid organ transplantation, where they are used to reduce acute rejection and support graft survival. Common agents in this class include tacrolimus and cyclosporine; tacrolimus was specifically highlighted in the provided studies as a representative calcineurin inhibitor.
Because of their potency, calcineurin inhibitors are also associated with important toxicities, especially nephrotoxicity. Their use is therefore often balanced against adjunctive or alternative agents such as everolimus, mycophenolate mofetil, sirolimus, and anti-Cd40-directed strategies in attempts to preserve immunologic efficacy while reducing renal injury and other complications. Beyond transplantation, tacrolimus has also been studied in non-transplant immune-mediated disorders and local tissue applications, reflecting the broader therapeutic relevance of calcineurin inhibition in controlling pathologic immune activation.
Where the papers sit
10 papers from the last 6 months study calcineurin inhibitor directly · updated from PubMed 12 Oct 2026
Study type 0 clinical trials · 4 observational · 2 human data · 4 preclinical
Themes no clear themes · 1 new direction
Those 10 do not share a common subject.
-
Tacrolimus and related immunosuppression appear across transplant care, autoimmune disease, tissue repair, and biomaterial studies. The transplant papers address long-term graft survival, cancer and infection risk, dysbiosis, and everolimus-based regimens. Other reports examine myasthenia gravis, keratoplasty, tracheal scarring, and nerve repair. No shared therapeutic direction emerges from this heterogeneous set.
Tacrolimus is repurposed as a local antifibrotic wound-healing agent
The chitosan/PLA/tacrolimus composite membrane for postoperative tracheal stenosis 42107578May moves tacrolimus beyond its established use as an immunosuppressive treatment or prophylactic adjunct. Instead, sustained local tacrolimus release selectively promoted normal tracheal fibroblast activity while suppressing hypertrophic-scar fibroblast proliferation and collagen production through reduced transforming growth factor-β and α-smooth-muscle-actin signaling. This gives the calcineurin inhibitor a non-immunosuppressive tissue-engineering role: preventing tracheal scarring while supporting wound repair.
Papers
The 10 papers from the last 6 months that study calcineurin inhibitor directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
No clear themes (10)
- A multi-national study examined the response sustainability to calcineurin inhibitors and long-term kidney survivals in children with genetic podocytopathies. Kidney international · 27 Jul 2026 PMID 42508611
- Immunosuppressive regimens and long-term kidney transplant outcomes: A dual survival modeling framework. PloS one · 26 Jun 2026 PMID 42361104
- Topical 0.02% tacrolimus as adjunctive immunoprophylaxis in high-risk penetrating keratoplasty: a four-year retrospective study. International ophthalmology · 19 Jun 2026 PMID 42319541
- Limited efficacy of a therapeutic anti-CD40 monoclonal antibody to inhibit activated CD4 T cell autoimmunity in vitro. PloS one · 12 Jun 2026 PMID 42284279
- Tacrolimus as Single-Agent Immunotherapy for Adult-Onset Myasthenia Gravis: Remission, Relapse, and Safety. CNS neuroscience & therapeutics · 1 Jun 2026 PMID 42223343
- Altered SIgA-targeting of gut microbiota is associated with long-term dysbiosis in pediatric solid organ transplant recipients. Gut microbes · 25 May 2026 PMID 42178721
- PEG-fusion of viable sciatic nerve isografts restores axonal structure and behavioral recovery after segmental-loss sciatic nerve injuries in Lewis rats. PloS one · 21 May 2026 PMID 42166429
- Chitosan nanoparticles-incorporated polylactic acid/tacrolimus nanofiber composite membrane for tracheal scar inhibition and tracheal wound healing promotion. International journal of biological macromolecules · 10 May 2026 PMID 42107578
- Tacrolimus-accelerated renal interstitial injury in subtotal nephrectomized rats and its pharmacological modulation by everolimus. Toxicology letters · 30 Apr 2026 PMID 42061595
- Clinical Impact and Cost-effectiveness of Everolimus Combination Therapy in Liver Transplant Recipients: Focus on the Risk of Cancer, Infection, and Renal Function. Transplantation · 23 Apr 2026 PMID 42024308
By study type
Observational studies and case reports (4)
- A multi-national study examined the response sustainability to calcineurin inhibitors and long-term kidney survivals in children with genetic podocytopathies. Kidney international · 27 Jul 2026 PMID 42508611
- Immunosuppressive regimens and long-term kidney transplant outcomes: A dual survival modeling framework. PloS one · 26 Jun 2026 PMID 42361104
- Topical 0.02% tacrolimus as adjunctive immunoprophylaxis in high-risk penetrating keratoplasty: a four-year retrospective study. International ophthalmology · 19 Jun 2026 PMID 42319541
- Tacrolimus as Single-Agent Immunotherapy for Adult-Onset Myasthenia Gravis: Remission, Relapse, and Safety. CNS neuroscience & therapeutics · 1 Jun 2026 PMID 42223343
Human data, design not indexed (2)
- Altered SIgA-targeting of gut microbiota is associated with long-term dysbiosis in pediatric solid organ transplant recipients. Gut microbes · 25 May 2026 PMID 42178721
- Clinical Impact and Cost-effectiveness of Everolimus Combination Therapy in Liver Transplant Recipients: Focus on the Risk of Cancer, Infection, and Renal Function. Transplantation · 23 Apr 2026 PMID 42024308
Preclinical: animal, cell and lab studies (4)
- Limited efficacy of a therapeutic anti-CD40 monoclonal antibody to inhibit activated CD4 T cell autoimmunity in vitro. PloS one · 12 Jun 2026 PMID 42284279
- PEG-fusion of viable sciatic nerve isografts restores axonal structure and behavioral recovery after segmental-loss sciatic nerve injuries in Lewis rats. PloS one · 21 May 2026 PMID 42166429
- Chitosan nanoparticles-incorporated polylactic acid/tacrolimus nanofiber composite membrane for tracheal scar inhibition and tracheal wound healing promotion. International journal of biological macromolecules · 10 May 2026 PMID 42107578
- Tacrolimus-accelerated renal interstitial injury in subtotal nephrectomized rats and its pharmacological modulation by everolimus. Toxicology letters · 30 Apr 2026 PMID 42061595
Written from 10 PubMed abstracts, each one listed by PMID above. Published: 2026-08-13. Last written: 2026-08-27 by GPT. Drafted by language models from published abstracts; not medical advice.